Methods of treating diabetes with Dll4 antagonists

Details for Australian Patent Application No. 2011210773 (hide)

Owner Regeneron Pharmaceuticals, Inc.

Inventors Skokos, Dimitris

Agent Watermark

Pub. Number AU-A-2011210773

PCT Pub. Number WO2011/094467

Priority 61/299,801 29.01.10 US; 61/388,697 01.10.10 US; 61/361,687 06.07.10 US

Filing date 28 January 2011

Wipo publication date 4 August 2011

International Classifications

C07K 16/22 Immunoglobulins, e.g. monoclonal or polyclonal antibodies

A61K 39/395 Medicinal preparations containing antigens or antibodies - Antibodies

A61P 3/10 Drugs for disorders of the metabolism

A61P 37/00 Drugs for immunological or allergic disorders

Event Publications

23 August 2012 PCT application entered the National Phase

  PCT publication WO2011/094467 Priority application(s): WO2011/094467

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2011210776-Improved water-soluble film having blend of PVOH polymers, and packets made therefrom

2011210771-Methods of treating autoimmune diseases with Dll4 antagonists